COVID-19 therapeutic clinical trials involving off-label, generics and those sponsored by small biotech generally continue to experience delays due to lack of awareness during the political season, consolidation of federal research power during the pandemic as well as testing notification delays. For those sponsors that aren’t part of the U.S. government's federally-driven “Operation Warp Speed,” such as the Montreal Heart Institute’s COLCORONA trial, this dynamic spells real trouble as a recent Harris Polling survey shows that 60% of Americans have never heard or read little to nothing about available clinical trials for newly diagnosed COVID-19 patients involving generic medications or drugs that are already approved for other uses. Mass media, social networks, and other information sources direct the masses to the sensationalism of political squabbles or the high-profile, big ticket vaccine studies or monoclonal antibody treatments. Other less known studies sponsored by small biotech or other generic or off-label studies are left in the corners of obscurity. The loser: the American people.
Lack of Media Access Terminal for Studies
Studies such as the COLCORONA trial are a...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).